Potential benefits associated with DPP-4 inhibitors include lower risk of hypoglycemia, neutral effect on weight, renoprotective effects, and lowering of BP
Low dose range: 100 to 150 mcg At this dose range, most people experience minimal to no side effects
Chinas Oral GLP-1 market is expanding rapidly in 2025 due to the countrys rising diabetes and obesity rates, with nearly 148 million diabetic adults and over 60% of the population overweight or obese, creating strong demand for effective glucose-lowering and weight-management therapies
An X-linked mitochondrial disease affecting cardiac muscle, skeletal muscle and neutrophil leucocytes
Gallery Does Thymosin Alpha-1 Boost Your Immune System
The injectable weight-loss drug Wegovy is the only medication currently approved for cardiovascular indications in patients with overweight or obesity and existing cardiovascular disease